These findings are attributable to the difficulty of differentiating infections resulting from immunosuppressive treatment and mTOR inhibitor-induced lung diseases, highlighting the need to carefully monitor the onset of pneumonia in patients treated with temsirolimus. This evidence concerns the gene MTOR and pneumonia.